Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 7/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 3/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14650758 | 0.88 | PRCP (0.53) | PRCPGRM5 | |
| SCHEMBL14650744 | 0.80 | PRCP (0.57) | PRCP | |
| SCHEMBL15894613 | 0.76 | PRCP (0.66) | PRCPMEN1KMT2A | |
| SCHEMBL12175462 | 0.76 | PRCP (0.58) | PRCP | |
| SCHEMBL5312189 | 0.74 | SIGMAR1 (0.49) | TACR1MEN1KMT2A | |
| SCHEMBL14650788 | 0.73 | PRCP (1.00) | PRCP | |
| SCHEMBL25359666 | 0.71 | MC4R (0.48) | MEN1KMT2ASTSMC4R | |
| SCHEMBL30623422 | 0.71 | MC4R (0.48) | MEN1KMT2ASTSMC4R | |
| SCHEMBL25358733 | 0.71 | MEN1 (0.45) | MEN1KMT2ASTSMC4R | |
| SCHEMBL30623464 | 0.71 | MEN1 (0.45) | MEN1KMT2ASTSMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563764-B1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, PEPD | PRCP 1/4885TACR1 809/4885CCR5 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.